Suchergebnisse - "Pajic, Marina"

Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer von Vennin, Claire, Murphy, Kendelle J, Morton, Jennifer P, Cox, Thomas R, Pajic, Marina, Timpson, Paul

“… Pancreatic cancer is accompanied with a fibrotic reaction that alters interactions between tumor cells and the stroma to promote tumor progression …”
Weitere Angaben

miR-139-5p Modulates Radiotherapy Resistance in Breast Cancer by Repressing Multiple Gene Networks of DNA Repair and ROS Defense von Pajic, Marina, Froio, Danielle, Daly, Sheridan, Doculara, Louise, Millar, Ewan, Graham, Peter H, Drury, Alison, Steinmann, Angela, de Bock, Charles E, Boulghourjian, Alice, Zaratzian, Anaiis, Carroll, Susan, Toohey, Joanne, O'Toole, Sandra A, Harris, Adrian L, Buffa, Francesca M, Gee, Harriet E, Hollway, Georgina E, Molloy, Timothy J

“… Radiotherapy is essential to the treatment of most solid tumors and acquired or innate resistance to this therapeutic modality is a major clinical problem …”
Weitere Angaben

Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth von Rath, Nicola, Munro, June, Cutiongco, Marie Francene, Jagiełło, Alicja, Gadegaard, Nikolaj, McGarry, Lynn, Unbekandt, Mathieu, Michalopoulou, Evdokia, Kamphorst, Jurre J, Sumpton, David, Mackay, Gillian, Vennin, Claire, Pajic, Marina, Timpson, Paul, Olson, Michael F

“… The high mortality of pancreatic cancer demands that new therapeutic avenues be developed. The orally available small-molecule inhibitor AT13148 potently …”
Weitere Angaben

Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma von Geleta, Bekesho, Park, Kyung Chan, Jansson, Patric J, Sahni, Sumit, Maleki, Sanaz, Xu, Zhihong, Murakami, Takashi, Pajic, Marina, Apte, Minoti V, Richardson, Des R, Kovacevic, Zaklina

“… Pancreatic cancer (PaCa) is characterized by dense stroma that hinders treatment efficacy, with pancreatic stellate cells (PSCs) being a major contributor to …”
Weitere Angaben

MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer von Cipponi, Arcadi, Goode, David L, Bedo, Justin, McCabe, Mark J, Pajic, Marina, Croucher, David R, Rajal, Alvaro Gonzalez, Junankar, Simon R, Saunders, Darren N, Lobachevsky, Pavel, Papenfuss, Anthony T, Nessem, Danielle, Nobis, Max, Warren, Sean C, Timpson, Paul, Cowley, Mark, Vargas, Ana C, Qiu, Min R, Generali, Daniele G, Keerthikumar, Shivakumar, Nguyen, Uyen, Corcoran, Niall M, Long, Georgina V, Blay, Jean-Yves, Thomas, David M

“… In microorganisms, evolutionarily conserved mechanisms facilitate adaptation to harsh conditions through stress-induced mutagenesis (SIM). Analogous processes …”
Weitere Angaben

MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma von Castillo, Lesley, Young, Adelaide I J, Mawson, Amanda, Schafranek, Pia, Steinmann, Angela M, Nessem, Danielle, Parkin, Ashleigh, Johns, Amber, Chou, Angela, Law, Andrew M K, Lucas, Morghan C, Murphy, Kendelle J, Deng, Niantao, Gallego-Ortega, David, Caldon, Catherine E, Timpson, Paul, Pajic, Marina, Ormandy, Christopher J, Oakes, Samantha R

“… Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies. It is phenotypically heterogeneous with a highly unstable genome and …”
Volltext

Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial von Chantrill, Lorraine A, Nagrial, Adnan M, Watson, Clare, Johns, Amber L, Martyn-Smith, Mona, Simpson, Skye, Mead, Scott, Jones, Marc D, Samra, Jaswinder S, Gill, Anthony J, Watson, Nicole, Chin, Venessa T, Humphris, Jeremy L, Chou, Angela, Brown, Belinda, Morey, Adrienne, Pajic, Marina, Grimmond, Sean M, Chang, David K, Thomas, David, Sebastian, Lucille, Sjoquist, Katrin, Yip, Sonia, Pavlakis, Nick, Asghari, Ray, Harvey, Sandra, Grimison, Peter, Simes, John, Biankin, Andrew V

“… Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy …”
Weitere Angaben

Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1 von Kryza, Thomas, Khan, Tashbib, Lovell, Scott, Harrington, Brittney S., Yin, Julia, Porazinski, Sean, Pajic, Marina, Koistinen, Hannu, Rantala, Juha K., Dreyer, Tobias, Magdolen, Viktor, Reuning, Ute, He, Yaowu, Tate, Edward W., Hooper, John D.

“… CUB domain-containing protein 1 (CDCP1) is an oncogenic orphan transmembrane receptor and a promising target for the detection and treatment of cancer …”
Volltext

Genome‐wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT‐ROBO, ITGA2 and MET signaling von Nones, Katia, Waddell, Nic, Song, Sarah, Patch, Ann‐Marie, Miller, David, Johns, Amber, Wu, Jianmin, Kassahn, Karin S., Wood, David, Bailey, Peter, Fink, Lynn, Manning, Suzanne, Christ, Angelika N., Nourse, Craig, Kazakoff, Stephen, Taylor, Darrin, Leonard, Conrad, Chang, David K., Jones, Marc D., Thomas, Michelle, Watson, Clare, Pinese, Mark, Cowley, Mark, Rooman, Ilse, Pajic, Marina, Butturini, Giovanni, Malpaga, Anna, Corbo, Vincenzo, Crippa, Stefano, Falconi, Massimo, Zamboni, Giuseppe, Castelli, Paola, Lawlor, Rita T., Gill, Anthony J., Scarpa, Aldo, Pearson, John V., Biankin, Andrew V., Grimmond, Sean M.

“… The importance of epigenetic modifications such as DNA methylation in tumorigenesis is increasingly being appreciated. To define the genome‐wide pattern of DNA …”
Volltext

TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma von Lundy, Joanne, Gearing, Linden J., Gao, Hugh, West, Alison C., McLeod, Louise, Deswaerte, Virginie, Yu, Liang, Porazinski, Sean, Pajic, Marina, Hertzog, Paul J., Croagh, Daniel, Jenkins, Brendan J.

“… Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis, and is plagued by a paucity of targeted treatment options and tumour resistance to …”
Volltext

RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas von Chou, Angela, Brown, Ian S., Kumarasinghe, M. Priyanthi, Perren, Aurel, Riley, Denise, Kim, Yoomee, Pajic, Marina, Steinmann, Angela, Rathi, Vivek, Jamieson, Nigel B., Verheij, Joanne, van Roessel, Stijn, Nahm, Chris B., Mittal, Anubhav, Samra, Jaswinder, Gill, Anthony J.

“… Pancreatic acinar cell carcinoma is relatively rare (1 to 2% of pancreatic malignancies) but may be under-recognized. In contrast to pancreatic ductal …”
Volltext

Systematic functional identification of cancer multi-drug resistance genes von Lau, Man-Tat, Ghazanfar, Shila, Parkin, Ashleigh, Chou, Angela, Rouaen, Jourdin R., Littleboy, Jamie B., Nessem, Danielle, Khuong, Thang M., Nevoltris, Damien, Schofield, Peter, Langley, David, Christ, Daniel, Yang, Jean, Pajic, Marina, Neely, G. Gregory

“… Background Drug resistance is a major obstacle in cancer therapy. To elucidate the genetic factors that regulate sensitivity to anti-cancer drugs, we performed …”
Volltext

Oncogenic proteome of pancreatic cancer extracellular vesicles: sodium/myo-inositol cotransporter as a potential marker von Panda, Arunima, Ragunath, Krish, Pajic, Marina, Greening, David W., Falasca, Marco

Volltext

Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater von Chang, David K, Jamieson, Nigel B, Johns, Amber L, Scarlett, Christopher J, Pajic, Marina, Chou, Angela, Pinese, Mark, Humphris, Jeremy L, Jones, Marc D, Toon, Christopher, Nagrial, Adnan M, Chantrill, Lorraine A, Chin, Venessa T, Pinho, Andreia V, Rooman, Ilse, Cowley, Mark J, Wu, Jianmin, Mead, R Scott, Colvin, Emily K, Samra, Jaswinder S, Corbo, Vincenzo, Bassi, Claudio, Falconi, Massimo, Lawlor, Rita T, Crippa, Stefano, Sperandio, Nicola, Bersani, Samantha, Dickson, Euan J, Mohamed, Mohamed A A, Oien, Karin A, Foulis, Alan K, Musgrove, Elizabeth A, Sutherland, Robert L, Kench, James G, Carter, C Ross, Gill, Anthony J, Scarpa, Aldo, McKay, Colin J, Biankin, Andrew V

“… Individuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the …”
Weitere Angaben

MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability von Ephraums, James, Youkhana, Janet, Raina, Aparna S., Schulstad, Grace, Croft, Kento, Mawson, Amanda, Kokkinos, John, Gonzales-Aloy, Estrella, Ignacio, Rosa Mistica C., McCarroll, Joshua A., Boyer, Cyrille, Goldstein, David, Pajic, Marina, Haghighi, Koroush S., Johns, Amber, Gill, Anthony J., Erkan, Mert, Initiative (APGI), Australian Pancreatic Cancer Genome, Phillips, Phoebe A., Sharbeen, George

“… Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of just 13 %. Conventional therapies fail due to acquired chemoresistance. We …”
Volltext

Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy von Satgunaseelan, Laveniya, Porazinski, Sean, Strbenac, Dario, Istadi, Aji, Willet, Cali, Chew, Tracy, Sadsad, Rosemarie, Palme, Carsten E., Lee, Jenny H., Boyer, Michael, Yang, Jean Y. H., Clark, Jonathan R., Pajic, Marina, Gupta, Ruta

“… There is an increasing worldwide incidence of patients under 50 years of age presenting with oral squamous cell carcinoma (OSCC). The molecular mechanisms …”
Volltext

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials von Nagrial, Adnan M., Chin, Venessa T., Sjoquist, Katrin M., Pajic, Marina, Horvath, Lisa G., Biankin, Andrew V., Yip, Desmond

“… •Use of second-line therapy was reported in 17% of randomised first-line studies.•Increased rates of second-line therapy correlated with improved overall …”
Volltext

Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer von Conway, James R.W., Warren, Sean C., Herrmann, David, Murphy, Kendelle J., Cazet, Aurélie S., Vennin, Claire, Shearer, Robert F., Killen, Monica J., Magenau, Astrid, Mélénec, Pauline, Pinese, Mark, Nobis, Max, Zaratzian, Anaiis, Boulghourjian, Alice, Da Silva, Andrew M., del Monte-Nieto, Gonzalo, Adam, Arne S.A., Harvey, Richard P., Haigh, Jody J., Wang, Yingxiao, Croucher, David R., Sansom, Owen J., Pajic, Marina, Caldon, C. Elizabeth, Morton, Jennifer P., Timpson, Paul

“… Application of advanced intravital imaging facilitates dynamic monitoring of pathway activity upon therapeutic inhibition. Here, we assess resistance to …”
Volltext

Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice von Pajic, Marina, Blatter, Sohvi, Guyader, Charlotte, Gonggrijp, Maaike, Kersbergen, Ariena, Küçükosmanoğlu, Aslι, Sol, Wendy, Drost, Rinske, Jonkers, Jos, Borst, Piet, Rottenberg, Sven

“… Purpose: We aimed to characterize and target drug-tolerant BRCA1-deficient tumor cells that cause residual disease and subsequent tumor relapse.Experimental …”
Weitere Angaben

qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles von Song, Sarah, Nones, Katia, Miller, David, Harliwong, Ivon, Kassahn, Karin S., Pinese, Mark, Pajic, Marina, Gill, Anthony J., Johns, Amber L., Anderson, Matthew, Holmes, Oliver, Leonard, Conrad, Taylor, Darrin, Wood, Scott, Xu, Qinying, Newell, Felicity, Cowley, Mark J., Wu, Jianmin, Wilson, Peter, Fink, Lynn, Biankin, Andrew V., Waddell, Nic, Grimmond, Sean M., Pearson, John V.

“… Tumour cellularity, the relative proportion of tumour and normal cells in a sample, affects the sensitivity of mutation detection, copy number analysis, cancer …”
Volltext